Aytu BioScience is expected to report a Q2 2026 consensus revenue of $24.52 million and an EPS loss of $0.22, with the current stock price of $2.85 trading well below the average analyst target of $7.00. The primary focus for investors this quarter is the prescription volume growth within the core ADHD portfolio, specifically the performance of Adzenys XR-ODT and Cotempla XR-ODT.
Following a significant commercial restructuring aimed at achieving profitability, the market is looking for sustained revenue expansion in the pediatric and ADHD segments. Analysts are specifically monitoring gross margin improvements and the effectiveness of the company’s leaner operating model in reducing cash burn.